NASDAQ · KOD
Kodiak Sciences Inc.
$100.40+$3.36 (+3.46%)
Kodiak Sciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.46% below the high.
Loading market information…
NASDAQ · BBOT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BridgeBio Oncology Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BridgeBio Oncology Therapeutics Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.69. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BridgeBio Oncology Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 11, 2025 |
| $0.12 |
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$0.74 | $0.00 |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $20.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$100.40+$3.36 (+3.46%)
Kodiak Sciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.46% below the high.
$22.53+$0.30 (+1.35%)
Tango Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.49% below the high.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$29.21-$0.78 (-2.6%)
Xencor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.07% below the high.
$45.23+$0.98 (+2.21%)
Septerna Inc’s quoted price sits in the upper half of its reported 52-week range, 11.49% below the high.
$33.48-$0.27 (-0.8%)
UroGen Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 34.11% below the high.
$20.69+$0.09 (+0.44%)
Mind Medicine (MindMed) Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.85% below the high.
$48.64-$1.86 (-3.68%)
AnaptysBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.78% below the high.
